Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results

被引：7

作者：

Chi, Kim N. ^{[1
]}

Fleshner, Neil ^{[2
]}

Chiuri, Vincenzo Emanuele ^{[3
]}

Van Bruwaene, Siska ^{[4
]}

Hafron, Jason ^{[5
]}

McNeel, Douglas G. ^{[6
]}

De Porre, Peter ^{[7
]}

Maul, Raymond Scott ^{[8
]}

Daksh, Mahesh ^{[9
]}

Zhong, Xiaogang ^{[10
]}

Mason, Gary E. ^{[11
]}

Tutrone, Ronald F. ^{[12
]}

机构：

[1] Univ British Columbia, BC Canc Vancouver Ctr, Vancouver, BC, Canada

[2] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] I Veris Delli Ponti Hosp, Lecce, Italy

[4] AZ Groeninge Hosp, Dept Urol, Kortrijk, Belgium

[5] Michigan Inst Urol, W Bloomfield, MI USA

[6] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[7] Janssen Res & Dev, Beerse, Belgium

[8] Janssen Res & Dev, Los Angeles, CA USA

[9] Janssen Res & Dev, Raritan, NJ USA

[10] Janssen Res & Dev, College Pk, MD USA

[11] Janssen Res & Dev, Spring House, PA USA

[12] Chesapeake Urol Res Assoc, Towson, MD USA

来源：

ONCOLOGIST | 2023年 / 28卷 / 05期

关键词：

castration-resistant prostate cancer; PARP inhibitor; homologous recombination repair; niraparib; abiraterone acetate;

D O I：

10.1093/oncolo/oyad008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous recombination repair gene alterations and had progressed on 1 prior line of novel androgen receptor-targeted therapy. Results from the combination of NIRA with abiraterone acetate plus prednisone, which disrupts androgen axis signaling through inhibition of CYP17, showed promising efficacy and a manageable safety profile in this patient population.

引用

页码：E309 / E312

页数：4

共 50 条

[31] New drugs in the treatment of metastatic castration-resistant prostate cancer: abiraterone acetate
Martinez-Hernandez, Lucia
Martinez-Prieto, Marcela
Galvan-Salazar, Gabriel
GACETA MEXICANA DE ONCOLOGIA, 2013, 12 (01): : 32 - 40
[32] A phase II study of onvansertib (PCM-075) in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer.
Einstein, David Johnson
Choudhury, Atish Dipankar
Saylor, Philip James
Werner, Lillian
Erlander, Mark G.
Ridinger, Maya
Bubley, Glenn
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[33] The development of abiraterone acetate for castration-resistant prostate cancer
Grist, Emily
Attard, Gerhardt
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (06) : 289 - 294
[34] Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer
Scott, Lesley J.
Yang, Lily P. H.
Lyseng-Williamson, Katherine A.
DRUGS & AGING, 2012, 29 (03) : 243 - 248
[35] Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer
Martini, Alberto
Fallara, Giuseppe
Ploussard, Guillaume
Malavaud, Bernard
LANCET ONCOLOGY, 2023, 24 (10): : 1056 - 1057
[36] A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Small, Eric J.
Lance, Raymond S.
Gardner, Thomas A.
Karsh, Lawrence I.
Fong, Lawrence
Mccoy, Candice
DeVries, Todd
Sheikh, Nadeem A.
Thakurta, Debraj Guha
Chang, Nancy
Redfern, Charles H.
Shore, Neal D.
CLINICAL CANCER RESEARCH, 2015, 21 (17) : 3862 - 3869
[37] A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Shore, Neal D.
Mellado, Begona
Shah, Satish
Hauke, Ralph J.
Costin, Dan
Morris, Thomas
Anjum, Rana
Szijgyarto, Zsolt
Verheijen, Remy B.
Cullberg, Marie
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[38] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
Mostaghel, Elahe A.
CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
[39] Abiraterone AcetateIn Metastatic Castration-Resistant Prostate Cancer
Lily P. H. Yang
Drugs, 2011, 71 : 2067 - 2077
[40] A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC).
Mckay, Rana R.
Werner, Lillian
Jones, Alexandra
Choudhury, Atish Dipankar
Pomerantz, Mark
Sweeney, Christopher
Bubley, Glenn J.
Slovin, Susan F.
Morris, Michael J.
Kantoff, Philip W.
Taplin, Mary-Ellen
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →